Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med 2006; 355: 2408–2417.

    Article  CAS  Google Scholar 

  2. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.

    Article  CAS  Google Scholar 

  3. Rosti G, Martinelli G, Bassi S, Amabile M, Tra bachi E, Giannini B et al. Molecular response to Imatinib in late chronic phase chronic myeloid leukemia. Blood 2004; 103: 2284–2290.

    Article  CAS  Google Scholar 

  4. Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL . Punish the parent not the progeny. Blood 2005; 105: 1862–1866.

    Article  CAS  Google Scholar 

  5. Cortes J, O'Brien S, Kantarjian H . Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204–2205.

    Article  CAS  Google Scholar 

  6. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60.

    Article  CAS  Google Scholar 

  7. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701–4707.

    Article  CAS  Google Scholar 

  8. Goldman J, Gordon M . Why do chronic myelogenous leukemia stem cells survive allogeneic stem celltransplantation or imatinib: does it really matter? Leuk Lymphoma 2006; 47: 1–7.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from PAR 2005, MIUR 2005, SIENAIL, Fondazione Monte dei Paschi. Informed consent was obtained from patients before entering into the study. M Bocchia designed research, analyzed data and wrote the paper. M Ippoliti performed research and analyzed data. A Gozzetti analyzed data and contributed in writing the manuscript. E Abruzzese contributed in designing the research and analyzing data. S Calabrese, R Crupi, D Tozzuoli, M Amabile and G Martinelli contributed in performing research. MM Trawinska, M Defina and MT Pirrotta collected and managed the clinical data. F Lauria supervised the research and revised the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Bocchia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bocchia, M., Ippoliti, M., Gozzetti, A. et al. CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. Leukemia 22, 426–428 (2008). https://doi.org/10.1038/sj.leu.2404893

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404893

This article is cited by

Search

Quick links